French vote for new patient charges

5 November 2007

The French National Assembly has backed the highly controversial introduction of non-reimbursable charges - the so-called franchise regimes - for drugs, paramedical care and patient transport (Marketletters passim). The charges will take effect from January 1 next year.

The Assembly vote went 44 to 27 in favor as part of the 2008 social security finance measures. The aim of the charges is to help reduce the health budget short fall, with an overall social security deficit estimated at 12.0 billion euros ($17.28 billion) for the current year.

Drug charges will be 0.50 euros per item and, along with the other levies, will be expected to save 850.0 million euros in 2008. Savings will be used to help fund Alzheimer's disease and cancer treatment programs, as well as palliative care. A survey in September showed that 70% of the French public was opposed to the charges. These have now been fixed at a maximum of 50 euros per year for each patient.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Today's issue

Company Spotlight